{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:12:12Z","timestamp":1780431132692,"version":"3.54.1"},"reference-count":21,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Adrenocortical carcinoma (ACC) is a rare and aggressive cancer with limited treatment options, commonly managed with mitotane, which can cause serious side effects, including central hypothyroidism and dyslipidemia. This study aimed to evaluate the incidence, clinical features, and relationship between mitotane-induced central hypothyroidism and dyslipidemia in ACC patients, as well as to investigate mitotane\u2019s direct toxic effects on thyroid cells. Thirty-eight ACC patients treated with mitotane for at least six months were monitored for thyroid function and lipid profiles. Central hypothyroidism developed in 50% of patients with normal baseline thyroid function, mostly women, who were at higher risk. Dyslipidemia occurred in 40% of patients, more frequently in men, and appeared earlier than hypothyroidism. In vitro experiments on rat thyroid cells demonstrated a dose-dependent toxic effect of mitotane on cell viability. No significant link was found between hypothyroidism and dyslipidemia risk. These findings reveal sex-specific susceptibilities to mitotane toxicity and provide novel evidence of direct mitotane-induced thyroid cell damage. This insight supports the need for careful thyroid and lipid profile monitoring during mitotane treatment and may inform the development of safer therapies for ACC.<\/jats:p>","DOI":"10.3390\/curroncol32120700","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:13:33Z","timestamp":1765538013000},"page":"700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mitotane-Induced Hypothyroidism and Dyslipidemia in Adrenocortical Carcinoma: Sex Differences and Novel Evidence from a Thyroid Cell Model"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4092-5107","authenticated-orcid":false,"given":"Irene","family":"Tizianel","sequence":"first","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8830-0947","authenticated-orcid":false,"given":"Arianna","family":"Beber","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Madinelli","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0059-5660","authenticated-orcid":false,"given":"Mario","family":"Caccese","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-2693","authenticated-orcid":false,"given":"Susi","family":"Barollo","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7931-0084","authenticated-orcid":false,"given":"Loris","family":"Bertazza","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-1275","authenticated-orcid":false,"given":"Elena","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Pain Therapy and Palliative Care Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6946-9673","authenticated-orcid":false,"given":"Simona","family":"Censi","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-8001","authenticated-orcid":false,"given":"Caterina","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: A practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant Therapies and Patient and Tumor Characteristics Associated With Survival of Adult Patients With Adrenocortical Carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Puglisi, S., Calabrese, A., Basile, V., Ceccato, F., Scaroni, C., Altieri, B., Della Casa, S., Loli, P., Pivonello, R., and De Martino, M.C. (2020). Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12030740"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Basile, V., Puglisi, S., Calabrese, A., Pia, A., Perotti, P., Berruti, A., Reimondo, G., and Terzolo, M. (2020). Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. Cancers, 12.","DOI":"10.3390\/cancers12092615"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/en.2009-1404","article-title":"Therapeutic Concentrations of Mitotane (o,p\u2032-DDD) Inhibit Thyrotroph Cell Viability and TSH Expression and Secretion in a Mouse Cell Line Model","volume":"151","author":"Zatelli","year":"2010","journal-title":"Endocrinology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.14345","article-title":"Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients","volume":"94","author":"Vikner","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bianchini, M., Puliani, G., Chiefari, A., Mormando, M., Lauretta, R., and Appetecchia, M. (2021). Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13195001"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000491388","article-title":"2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism","volume":"7","author":"Persani","year":"2018","journal-title":"Eur Thyroid J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"120479","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11883-023-01142-x","article-title":"Fixed Combination for the Treatment of Dyslipidaemia","volume":"25","author":"Ferri","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ghasemi, M., Turnbull, T., Sebastian, S., and Kempson, I. (2021). The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312827"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"pdb.prot095505","DOI":"10.1101\/pdb.prot095505","article-title":"Analysis of Cell Viability by the MTT Assay","volume":"2018","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1210\/clinem\/dgad115","article-title":"Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline","volume":"108","author":"Poirier","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1210\/jcem-48-6-989","article-title":"Thyrotropin Secretion in Patients with Central Hypothyroidism: Evidence for Reduced Biological Activity of Immunoreactive Thyrotropin","volume":"48","author":"Faglia","year":"1979","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","first-page":"3631","article-title":"Circulating Thyrotropin Bioactivity in Sporadic Central Hypothyroidism","volume":"85","author":"Borgato","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"624962","DOI":"10.1155\/2013\/624962","article-title":"Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study","volume":"2013","author":"Shawa","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e210002","DOI":"10.1530\/EC-21-0002","article-title":"Update on dyslipidemia in hypothyroidism: The mechanism of dyslipidemia in hypothyroidism","volume":"11","author":"Liu","year":"2022","journal-title":"Endocr. Connect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/oncolo\/oyae084","article-title":"A review of mitotane in the management of adrenocortical cancer","volume":"29","author":"Else","year":"2024","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/07435800.2024.2402311","article-title":"Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma","volume":"50","year":"2025","journal-title":"Endocr. Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/700\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:40:28Z","timestamp":1765539628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["curroncol32120700"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32120700","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}